Rechallenge with Anti-EGFR Treatment in RAS/BRAF wt Metastatic Colorectal Cancer (mCRC) in Real Clinical Practice: Experience of the GITuD Group.

Mercedes Salgado FernándezMargarita Reboredo LópezMarta Covela RúaSonia CandamioPaula González-VillarroelLuis Felipe Sánchez-CousidoBegoña GrañaAlberto Carral-MasedaSoledad Cameselle-GarcíaVanesa Varela PoseMaria Elena Gallardo-MartínNieves Martínez-Lagonull null

Published in: Targeted oncology (2024)

In RAS/BRAF wt mCRC patients, an anti-EGFR rechallenge provides a feasible therapeutic option with clinical benefit (survival) and a manageable safety profile.

Keyphrases

metastatic colorectal cancer
wild type
small cell lung cancer
end stage renal disease
clinical practice
epidermal growth factor receptor
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
prognostic factors
patient reported outcomes
free survival